Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05601544 · ClinicalTrials.gov registry record · NA
The Effects of Contact Lenses With UV/HEV-Filter on Visual Function
A NA study, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 145
- Enrollment target
NCT05601544: Completed NA study, sponsored by Johnson & Johnson Vision Care.
NCT05601544 is a NA study that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 145 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05601544, a NA study, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 145 participants
- Enrollment target
Study Summary
This is a 2-phase, single-site, non-dispensing, randomized, controlled, double-masked, 2x2 crossover study to objectively measure potential benefits of a new UV/HEV filter using psychophysical testing techniques.
Primary Outcome
Visual range is defined as the log relative energy of simulated haze needed to obscure an otherwise high contrast grating target. Better visual range is indicated by a higher log-relative energy (LRE) of simulated haze (more haze) to obscure an otherwise highly visible target.
Interventions
- DEVICE ACUVUE OASYS 1-Day for Astigmatism
- DEVICE ACUVUE OASYS 1-Day
- DEVICE ACUVUE OASYS MAX 1-Day
- DEVICE ACUVUE OASYS Multifocal
- DEVICE ACUVUE OASYS MAX 1-Day Multifocal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2022-12-09 |
| Est. Completion | 2023-11-17 |
| Phase | NA |
What the finished NCT05601544 record still lists
NCT05601544 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 5 interventions - of which ACUVUE OASYS 1-Day for Astigmatism is the first listed.
NCT05601544 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05601544 about?
NCT05601544 is a clinical study titled "The Effects of Contact Lenses With UV/HEV-Filter on Visual Function". This is a 2-phase, single-site, non-dispensing, randomized, controlled, double-masked, 2x2 crossover study to objectively measure potential benefits of a new UV/HEV filter using psychophysical testing techniques.
What is the current status of trial NCT05601544?
This trial is currently completed. It is a NA study. The enrollment target is 145 participants. The study started on 2022-12-09. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT05601544?
The interventions under investigation include: ACUVUE OASYS 1-Day for Astigmatism (DEVICE), ACUVUE OASYS 1-Day (DEVICE), ACUVUE OASYS MAX 1-Day (DEVICE), ACUVUE OASYS Multifocal (DEVICE), ACUVUE OASYS MAX 1-Day Multifocal (DEVICE).
Who is sponsoring clinical trial NCT05601544?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05601544's enrollment target sits among peer trials
145 705th of 2000 higher than 1,295 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI